{
    "organizations": [],
    "uuid": "280bcecd91a2fc6954aeead91d92f8de874f1b6b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aimmune-therapeutics-phase-3-palis/brief-aimmune-therapeutics-phase-3-palisade-trial-of-ar101-meets-primary-endpoint-in-patients-with-peanut-allergy-idUSASB0C6CG",
    "ord_in_thread": 0,
    "title": "BRIEF-Aimmune Therapeutics' Phase 3 Palisade Trial Of Ar101 Meets Primary Endpoint In Patients With Peanut Allergy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Aimmune Therapeutics Inc:\n* AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY\n* AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY\n* AIMMUNE THERAPEUTICS-LOWER-BOUND OF 95% CONFIDENCE INTERVAL OF DIFFERENCE BETWEEN TREATMENT ARMS AT PRIMARY ENDPOINT WAS 53.0, GREATLY EXCEEDING PRE-SPECIFIED THRESHOLD OF 15%\n* AIMMUNE THERAPEUTICS-AMONG PATIENTS AGES 4-17 WHO COMPLETED TREATMENT WITH AR101, 96.3% TOLERATED A 300-MG DOSE OF PEANUT PROTEIN IN EXIT FOOD CHALLENGE\n* AIMMUNE THERAPEUTICS SAYS 2.4% OF AR101 PATIENTS AGES 4-17 AND 0.8% OF PLACEBO PATIENTS EXPERIENCED SERIOUS ADVERSE EVENTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-20T20:28:00.000+02:00",
    "crawled": "2018-02-21T21:35:05.027+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "aimmune",
        "therapeutic",
        "inc",
        "aimmune",
        "therapeutic",
        "pivotal",
        "phase",
        "palisade",
        "trial",
        "ar101",
        "meet",
        "primary",
        "endpoint",
        "patient",
        "peanut",
        "allergy",
        "aimmune",
        "therapeutic",
        "pivotal",
        "phase",
        "palisade",
        "trial",
        "ar101",
        "meet",
        "primary",
        "endpoint",
        "patient",
        "peanut",
        "allergy",
        "aimmune",
        "confidence",
        "interval",
        "difference",
        "treatment",
        "arm",
        "primary",
        "endpoint",
        "greatly",
        "exceeding",
        "threshold",
        "aimmune",
        "patient",
        "age",
        "completed",
        "treatment",
        "ar101",
        "tolerated",
        "dose",
        "peanut",
        "protein",
        "exit",
        "food",
        "challenge",
        "aimmune",
        "therapeutic",
        "say",
        "ar101",
        "patient",
        "age",
        "placebo",
        "patient",
        "experienced",
        "serious",
        "adverse",
        "event",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}